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Abstract
Background: Cyclophilin A (CypA) represents a potential target for antiretroviral therapy since inhibition of CypA
suppresses human immunodeficiency virus type 1 (HIV-1) replication, although the mechanism through which
CypA modulates HIV-1 infectivity still remains unclear. The interaction of HIV-1 viral protein R (Vpr) with the human
peptidyl prolyl isomerase CypA is known to occur in vitro and in vivo. However, the nature of the interaction of
CypA with Pro-35 of N-terminal Vpr has remained undefined.
Results: Characterization of the interactions of human CypA with N-terminal peptides of HIV-1 Vpr has been
achieved using a combination of nuclear magnetic resonace (NMR) exchange spectroscopy and surface plasmon
resonance spectroscopy (SPR). NMR data at atomic resolution indicate prolyl cis/trans isomerisation of the highly
conserved proline residues Pro-5, -10, -14 and -35 of Vpr are catalyzed by human CypA and require only very low
concentrations of the isomerase relative to that of the peptide substrates. Of the N-terminal peptides of Vpr only
those containing Pro-35 bind to CypA in a biosensor assay. SPR studies of specific N-terminal peptides with
decreasing numbers of residues revealed that a seven-residue motif centred at Pro-35 consisting of RHFPRIW,
which under membrane-like solution conditions comprises the loop region connecting helix 1 and 2 of Vpr and
the two terminal residues of helix 1, is sufficient to maintain strong specific binding.
Conclusions: Only N-terminal peptides of Vpr containing Pro-35, which appears to be vital for manifold functions
of Vpr, bind to CypA in a biosensor assay. This indicates that Pro-35 is essential for a specific CypA-Vpr binding
interaction, in contrast to the general prolyl cis/trans isomerisation observed for all proline residues of Vpr, which
only involve transient enzyme-substrate interactions. Previously suggested models depicting CypA as a chaperone
that plays a role in HIV-1 virulence are now supported by our data. In detail the SPR data of this interaction were
compatible with a two-state binding interaction model that involves a conformational change during binding. This
is in accord with the structural changes observed by NMR suggesting CypA catalyzes the prolyl cis/trans
interconversion during binding to the RHFP35RIW motif of N-terminal Vpr.
Background
The 96 amino acid virion-associated multifunctional
viral protein R (Vpr) [1,2] is encoded by primate lenti-
viruses, the human immunodeficiency viruses, types 1
and 2 (HIV-1/HIV-2), and simian immunodeficiency
viruses (SIV). This accessory protein fulfils multiple
functions in the viral life cycle including increase of
viral replication in non-dividing host cells, induction of
G2 cell-cycle arrest [3,4], apoptosis [5,6], and transduc-
tion through cell membranes [7]. Vpr facilitates trans-
port of the pre-integration complex into the nucleus of
non-dividing cells [8] and interacts with several cellular
factors, including the human peptidyl prolyl isomerase
CypA [9].
The interaction of HIV-1 Vpr with CypA is known to
occur in vitro and in vivo [9-11]. In addition to the
extensively studied interaction between CypA and HIV-
1 capsid, that is crucial for viral replication [12,13],
* Correspondence: Torgils.Fossen@kj.uib.no
1From the Department of Chemistry, University of Bergen, N-5007 Bergen,
Norway
Full list of author information is available at the end of the article
Solbak et al. BMC Structural Biology 2010, 10:31
http://www.biomedcentral.com/1472-6807/10/31
© 2010 Solbak et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
CypA was also reported to be significant for the de novo
synthesis of Vpr, as the Vpr-mediated cell cycle arrest in
HIV-1 infected T cells appeared to be eliminated in the
absence of CypA activity [9]. However, more recently
Ardon et al. [10] concluded that the interaction of Vpr
with CypA is independent of the ability of Vpr to induce
cell cycle arrest. Nonetheless, specific inhibitors of the
prolyl cis/trans isomerase activity of CypA, such as
cyclosporine A and SDZ-NIM811 inhibit HIV replica-
tion [11,14-18].
Previous structural studies of Vpr by 2D NMR spec-
troscopy in aqueous organic solvents provided evidence
of proline cis/trans isomerism for the highly conserved
N-terminal Pro-5, -10, -14 and -35 of Vpr [19]. In parti-
cular Pro-35 exhibited a relatively high proportion of
the cis isomer under these solvent conditions (15% cis
isomer content). This suggested prolyl cis/trans isomeri-
sation may be important for the folding of the molecule.
At pH 7 Vpr has a relatively random structure in aqu-
eous solution but assumes a folded structure in a hydro-
phobic membranous environment [7,19]. This fact
together with observation of considerable amounts of
CypA in virions [20] prompted a study, using surface
plasmon resonance (SPR) spectroscopy, of the interac-
tion of Vpr with the prolyl cis/trans isomerase CypA
[9]. A qualitative interaction was detected for N-term-
inal peptides containing Pro-35, indicating an essential
role for this Pro residue, although this could not be
quantified. Indeed the interaction of Vpr with CypA
could not be confirmed under the solution conditions
used. Hence, the nature of the interaction of CypA with
Pro-35 of N-terminal Vpr has remained undefined.
The catalytic activity of CypA, as a peptidyl-prolyl cis/
trans isomerase (PPiase), has previously been studied on
short model peptides containing one Pro residue. Thus,
based on interaction studies of eight short model pep-
tides, each comprising four residues containing only one
Pro residue preceded by a variety of different amino
acids, Harrison and Stein [21] concluded that CypA
exhibited a broad tolerance as a prolyl cis/trans isomer-
ase of several substrates. Endrich et al. [22] reported
that CypA interacts with three 14-37 residues HIV-1
Capsid-derived peptides, each containing 1-4 Pro resi-
dues and at least one Gly-Pro motif. However, exact
information regarding the interaction of individual Pro
residues within peptides containing more than one Pro
unit was not accessible with the applied methodology.
The suitability of NMR spectroscopy for studying the
catalytic activity of CypA has been demonstrated in a
more limited number of reports. NMR spectroscopy is
the only method wherefrom information about prolyl
cis/trans isomerase interaction of CypA with individual
Pro residues of a peptide, containing several Pro resi-
dues, is accessible at atomic resolution. However when
determined, only selective interactions involving one of
the Pro residues in the peptides [12,23] or the full
length protein [13] containing more than one Pro resi-
due have been reported.
In this paper the interactions of CypA with the N-
terminal synthetic Vpr (sVpr) peptides sVpr1-20, sVpr21-40
and sVpr25-40, containing all the highly conserved Pro
residues of Vpr, have been studied by NMR spectroscopy
at atomic resolution. The NMR experiments were per-
formed in aqueous phosphate buffer at physiological pH
7, where CypA retains its enzymatic activity and Vpr
exists in an unstructured state [7,19]. Complementary
experiments, using SPR spectroscopy and NMR spectro-
scopy, have provided an unambiguous distinction
between the substrate requirements for the catalytic
activity of CypA and those for a strong specific binding
to N-terminal Vpr. For the first time this has also allowed
quantification of this interaction.
Results
The combination and access to both highly pure recom-
binant CypA and synthetic N-terminal Vpr peptides, as
well as sensitive NMR and SPR facilities, has allowed us
to probe the interactions of Vpr and CypA in more
detail than previously.
Characterization of sVpr1-20, sVpr25-40 and sVpr21-40 by
NMR spectroscopy
Previous studies [7,19,24,25] have shown that Vpr has a
relatively random structure in aqueous solution at pH 7,
but has a propensity for three well-defined a-helical
structural domains in aqueous solution at lower pH or
in the presence of organic co-solvent (TFE-d2 or
CD3CN), where the extent of secondary structure is
dependent on the hydrophobicity of the solvent.
The N-terminal region of Vpr includes four highly
conserved Pro residues at positions 5, 10, 14 and 35,
respectively (Fig. 1) (more than 98% conserved accord-
ing to references [19] and [26]). Among these, the pre-
sence of Pro-35 is vital for several functional
interactions of Vpr. The tertiary structure of Vpr
observed in aqueous and 30% aqueous acetonitrile solu-
tion at low pH is characterized by a hydrophobic core
formed by the three a-helices [25] and partly reliant on
the presence of the Pro-35 residue that acts as a helix
breaker between helix 1 comprising residues 17-33, in
which the p6 binding domain of Vpr is located [27], and
helix 2 (comprising residues 38-50) of Vpr [28]. At pH
7 Vpr is essentially unstructured in aqueous solution
and requires under these conditions a hydrophobic
environment to achieve a-helical structure [7,19] (Addi-
tional file 1, Fig. S1).
In an initial series of 2D NMR experiments (2D 1H
TOCSY, ROESY and NOESY NMR spectra), the 1H
Solbak et al. BMC Structural Biology 2010, 10:31
http://www.biomedcentral.com/1472-6807/10/31
Page 2 of 15
chemical shifts of the all-trans isomers of sVpr1-20,
sVpr21-40 and sVpr25-40 in aqueous phosphate buffer
solution at pH 7 containing 10% v/v D2O were comple-
tely assigned (Additional file 1, Table S1, Additional file
1, Table S2, Additional file 1, Table S3, Additional file 1,
Table S4, Additional file 1, Table S5, Additional file 1,
Table S6 and Additional file 1, Table S7). In accordance
with previous investigations in aqueous organic solvent
[19] the NMR spectra of sVpr1-20 revealed two sets of
1H NMR signals originating from the same residues in
the sequence (Fig. 2). In each case one set of signals was
more intense than the second set, and the correspond-
ing amidic protons showed significant chemical shift dif-
ferences. The fact that the residues showing the largest
shift differences were those either adjacent to or very
close to each of the Pro residues indicated that the
weaker sets of signals in each case arose from the cis
isomers of the Pro residues. The identification of sets of
signals for Ala-4, Gly-9 and Tyr-15 (Fig. 2A), in addition
to the 1H NMR signals originating from the cis isomers
of Pro-5 and 14 (Fig. 3), is a strong indication that all
Pro residues are involved in such processes under the
conditions used. Similarly, 1H NMR signals originating
from the cis isomer of Pro-35 were observed in the 2D
1H NMR spectra of sVpr21-40 (Fig. 2B) and sVpr25-40.
It is particularly noteworthy that exchange peaks
between analogous 1H signals of the cis and trans iso-
mer were not observed in the NOESY spectra of any of
the pure peptides, which is a clear indication that only a
slow cis/trans interconversion on the NMR time scale is
taking place in the absence of enzymatic catalysis. As a
consequence of the relatively large energy barrier, unca-
talyzed isomerisation is a rather slow process with an
interconversion time on the order of several minutes
[29,30].
CypA catalyzes the prolyl cis/trans isomerisation of Pro-35
of sVpr21-40 and sVpr25-40
NMR spectroscopy provides information about prolyl
cis/trans isomerase interaction of CypA with Pro-con-
taining peptides and proteins at atomic resolution. Ori-
ginally, prolyl cis/trans isomerase activity of CypA with
relatively short model peptides, containing one Pro resi-
due, was revealed by line shape analysis of 1 D spectra
[31-33]. Exchange spectroscopy including 2D 1H-1H
NOESY and ROESY NMR experiments have been
applied to determine prolyl cis/trans isomerase interac-
tions of CypA with unlabelled model peptides
[23,34,35]. Selective interaction of Pro-90 of HIV-1 Cap-
sid was revealed by 3D 15N-edited NOESY-HSQC of
15N-labelled N-terminal (1-146) and full-length HIV-1
Capsid, in addition to a fragment of the HIV-1 Gag
polyprotein containing the full Matrix protein and the
N-terminal domain of Capsid [12,13].
When the complete series of NMR experiments
allowing full assignment of the 1H chemical shifts of
Figure 1 Interactions of N-terminal Vpr with CypA. Schematic overview of the N-terminal sequence of HIV-1NL4-3 Vpr showing its interactions
with CypA that include regions undergoing transient enzymatic prolyl cis/trans catalysis and the region of strong selective binding. In aqueous
phosphate buffer at pH 7 N-terminal Vpr peptides, as well as full-length Vpr, are essentially unstructured but assume a-helical structure at lower
pH and under hydrophobic conditions [7,19]. Notice that the region of selective strong binding of Vpr with CypA includes the entire loop region
connecting regions that form a-helices 1 and 2.
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sVpr21-40 were recorded, CypA was added to the peptide
solution at a molar ratio sVpr21-40-CypA 140:1, and ana-
logous NMR experiments were then recorded. In the
presence of catalytic amounts of CypA, strong exchange
peaks between related signals of the cis Pro-35 and
trans-Pro-35 isomer of sVpr21-40 were observed (Fig. 4A,
C and 4E). In particular, strong exchange peaks between
cis-Ha/trans-Ha and cis-Hδ/trans-Hδ of Pro-35 were
observed in the NOESY spectra after addition of cataly-
tic amounts of CypA.
Figure 2 Presence of cis and trans proline isomers in N-terminal sVpr. A1: Fingerprint region of the 2D
1H-1H TOCSY spectrum showing the
assigned spin systems of residues close to proline residues in sVpr(1-20) and A2: Superimposed expanded HN-HN regions of the 2D
1H-1H
NOESY spectra of sVpr1-20 in H2O:D2O (9:1, v/v) at pH 7 prior to (red signals) and after addition of 50 μl (0.1 mg) CypA (green signals). Notice the
appearance of exchange peaks originating from enhanced prolyl cis/trans interconversion rate after addition of CypA. B1: Expanded Ha-Hb
region of the 2D 1H-1H TOCSY spectrum of sVpr21-40 in H2O:D2O (9:1, v/v) at pH 7 showing the signals of trans and cis Pro-35. B2: Superimposed
expanded Ha-Hb regions of the 2D 1H-1H NOESY spectra of sVpr21-40 in H2O:D2O (9:1, v/v) at pH 7 prior to (red signals) and after addition of 100
μl (0.2 mg) CypA (green signals). Notice the appearance of exchange peaks originating from enhanced prolyl cis/trans interconversion rate after
addition of CypA.
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To confirm that CypA interacts with Pro-35 of sVpr21-40
and Pro-35 of sVpr25-40 as a prolyl cis/trans isomerase, an
excess of cyclosporine A (CsA), a selective inhibitor of
prolyl cis/trans isomerase activity of CypA was added, and
a complete series of NMR spectra were again recorded.
The NOESY and ROESY NMR spectra of sVpr21-40, after
the sequential addition of CypA and cyclosporine A,
revealed that the prolyl cis/trans exchange crosspeaks dis-
appeared after addition of cyclosporine A, and the NMR
spectra closely resembled those of pure sVpr21-40 (Fig. 4B,
D and 4F). Similar results were observed for sVpr25-40.
Thus, CypA behaves as a prolyl cis/trans isomerase, caus-
ing an increase in the interconversion rate of Pro-35 of
Vpr.
CypA catalyzes the prolyl cis/trans interconversion of Pro-
5, -10 and -14 of sVpr1-20
The NMR spectra of sVpr1-20 in aqueous phosphate buf-
fer at pH 7 revealed cis/trans proline isomerism of all
Pro residues of this peptide through the observation of
separate signals for the all-trans and various cis isomers
originating from a slow equilibrium under non-catalytic
conditions.
In order to reveal a potential interaction of CypA
with the highly conserved Pro-5, -10 and -14 of Vpr,
complete series of NMR experiments allowing full
assignment of the 1H chemical shifts of sVpr1-20 were
recorded, followed by addition of catalytic amounts of
CypA (molar ratio sVpr1-20-CypA 224:1; molar ratio
sVpr1-20 proline substrate-CypA 672:1). After addition
of catalytic amounts of CypA, particularly the HN-HN
region of the 2D 1H-1H NOESY NMR spectrum of
sVpr1-20 showed strong cis/trans exchange peaks
between related protons of the all-trans isomer and
various cis isomers originating from cis Pro-5, cis Pro-
10 and cis Pro-14, respectively (Fig. 5A). This was
further confirmed by the observation of exchange
peaks for Ha of Gly-9 and those of Hδ of Pro-5 and
Pro-14 (Fig. 3A). As described above for sVpr21-40 con-
taining Pro-35, cyclosporine A was added and a
further series of NMR spectra was recorded that
showed the disappearance of the prolyl cis/trans
exchange crosspeaks (Fig. 3B and 5B). Although Pro-5,
-10 and -14 of Vpr are highly conserved [31], any
interactions involving these residues have not pre-
viously been identified.
Thus we have direct experimental evidence that all four
conserved Pro residues in Vpr undergo cis/trans isomer-
ism in aqueous solution at pH 7 that is catalyzed by
CypA. Only small amounts of enzyme are required and
the NMR method is sufficiently sensitive to detect these
effects in ratios of substrate to enzyme as high as 672:1.
The applied relative proportions of enzyme to substrate
were considerably lower than the relative proportions of
Figure 3 Catalysis of isomerisation of Pro-5,10 and 14 of Vpr1-20 by CypA. A: Superimposed expanded Ha-Hb region of the 2D 1H-1H
NOESY spectra of sVpr1-20 in H2O:D2O (9:1, v/v) at pH 7 prior to (red signals) and after addition of 50 μl (0.1 mg) CypA (green signals). Notice the
appearance of exchange peaks originating from enhanced prolyl cis/trans interconversion rate after addition of CypA. B: Superimposed
expanded Ha-Hb region of the 2D 1H-1H NOESY spectra of sVpr1-20 in H2O:D2O (9:1, v/v) at pH 7 after addition of 50 μl (0.1 mg) CypA (green
signals) and after additional addition of 5 μl (0.1 mg) cyclosporine A (red signals). Notice that the prolyl cis/trans related exchange peaks
detected after addition of CypA disappear after addition of cyclosporine A.
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Figure 4 Catalysis of isomerisation of Pro-35 of Vpr21-40 by CypA. A, C, E: Superimposed expanded Ha-Hb regions of the 2D 1H-1H NOESY
spectra of sVpr21-40 in H2O:D2O (9:1, v/v) at pH 7 prior to (red signals) and after addition of 100 μl (0.2 mg) CypA (green signals). Notice the
appearance of exchange peaks originating from enhanced prolyl cis/trans interconversion rate after addition of CypA. B, D, F: Superimposed
expanded Ha-Hb region of the 2D 1H-1H NOESY spectra of sVpr21-40 in H2O:D2O (9:1, v/v) at pH 7 after addition of 100 μl (0.2 mg) CypA (green
signals) and after additional addition of 5 μl (0.1 mg) cyclosporine A (red signals). Notice that the prolyl cis/trans related exchange peaks
detected after addition of CypA disappear after addition of cyclosporine A.
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CypA (enzyme to substrate 1:8-1:300) used in previous
studies with NMR techniques [12,13,23,31-35].
Determination of cis/trans interconversion rate by ROESY
NMR experiments
To obtain the rate constant of the prolyl cis/trans inter-
conversion, a series of ROESY experiments with variable
mixing times were performed (Additional file 1, Table
S8 and Additional file 1, Fig. S2). For each mixing time,
volume integration of the well-resolved prolyl cis/trans
exchange crosspeaks originating from cisHaPro-35
-transHaPro-35 were performed, and based thereupon,
the reaction rate constant was calculated. The mean
reaction rate was calculated using the data from ROESY
experiments with mixing times 200-500 ms. Mean reac-
tion rate constant for the prolyl cis/trans interconver-
sion was determined to be 0.19 ± 0.01 s-1
Characterization of CypA-Vpr interaction using surface
plasmon resonance spectroscopy
Previous Biacore studies [9] concluded that Pro-35 was
a determinant for the ability of N-terminal Vpr peptides
to interact with CypA. sVpr1-20 or any mutant N-term-
inal Vpr peptide lacking Pro-35 did not interact with
CypA in the Biacore assay. Pure enzymatic interactions
such as the observed catalysis of prolyl cis/trans
isomerisation of N-terminal Vpr peptides by CypA will
not be detected by SPR because of the short lifetime of
the enzyme-substrate (ES) complexes (between 10-7 and
10-4 sec according to references [36] and [37]). We con-
firmed that the N-terminal peptides sVpr1-40, sVpr21-40
and the mutant sVpr1-40 P5,10,14N bind to CypA, while
sVpr1-20 and the mutant sVpr1-40 P35N failed to bind
(Fig. 6). Thus, the binding region of N-terminal Vpr
peptides for the observed interaction with CypA subse-
quently involves Pro-35.
Kinetic analysis of the Biacore binding data showed
deviations from a pseudo-first order 1:1 binding model.
The binding curves of CypA with sVpr25-40, sVpr21-40,
sVpr1-40 and the short peptides sVpr30-40 and sVpr32-38
were best described by a two-state binding interaction
model (Fig. 7, Additional file 1, Fig. S3). The minor
deviation observed between the experimental and mod-
elled curve for sVpr21-40 at the highest concentration, i.
e. 400 μM, may be due to aggregation of the peptide at
this concentration. The two-state binding model, also
called the conformational change model, is based on a
1:1 binding of an analyte to the immobilized ligand fol-
lowed by a conformational change in the complex. This
model should be regarded as indicative, rather than as
direct evidence, for a conformational change upon bind-
ing [38]. However, our NMR data confirm that CypA
Figures 5 Catalysis of isomerisation of Pro-5,10 and 14 of Vpr1-20 by CypA. A: Superimposed expanded HN-HN regions of the 2D 1H-1H
NOESY spectra of sVpr1-20 in H2O:D2O (9:1, v/v) at pH 7 prior to (red signals) and after addition of 50 μl (0.1 mg) CypA (green signals). Notice the
appearance of exchange peaks originating from enhanced prolyl cis/trans interconversion rate after addition of CypA. B: Superimposed
expanded HN-HN regions of the 2D 1H-1H NOESY spectra of sVpr1-20 in H2O:D2O (9:1, v/v) at pH 7 after addition of 50 μl (0.1 mg) CypA (green
signals) and after additional addition of 5 μl (0.1 mg) cyclosporine A (red signals). Notice that the prolyl cis/trans related exchange peaks
detected after addition of CypA disappear after addition of cyclosporine A.
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acts as a prolyl cis/trans isomerase of the highly con-
served Pro residues of N-terminal Vpr including Pro-35,
hence a conformational change upon binding is prob-
able. Thus, CypA catalyzes the prolyl cis/trans intercon-
version during binding to the sVpr peptides. The
interconversion rate constant derived from the ROESY
NMR experiments was determined to be 0.19 ± 0.01 s-1.
Thus, a peptide-CypA complex would undergo approxi-
mately 12 prolyl cis/trans interconversions during the 60
sec. association phase of the Biacore experiment. From
the two-state binding model the association rate (ka1),
dissociation rate (kd1), forward rate (ka2) and backward
Figure 6 Characterization of CypA binding to N-terminal peptides of sVpr. Synthetic Vpr1-20(A), Vpr21-40 (B), Vpr25-40 (C), Vpr1-40(D) and
synthetic mutants carrying Pro to Asn exchanges at amino acid positions 5, 10 and 14(sVpr1-40P5,10,14N) (E) and at position 35 (sVpr1-40 P35N)
(F) were tested for binding to immobilized recombinant CypA using a SPR biosensor system. A, B and C were injected at concentrations ranging
from 0-400 μM over CM5 chip immobilized with 918 RU CypA, while D, E and F were injected at concentrations ranging from 0-200 μM. The
curves A, B, C, D and E were best fit to a two state reaction model (Fig. 7). ka1, ka2, kd1, kd2 and KD were calculated for respective sensograms
(Table 1).
Solbak et al. BMC Structural Biology 2010, 10:31
http://www.biomedcentral.com/1472-6807/10/31
Page 8 of 15
Figure 7 Optimized fit of SPR sensograms to binding models. The sensograms were fit to the binding models 1:1 (Langmuir) (A1-G1) and
two-state reaction (conformational change) model (A2-G2). Black lines show the best curve fit in each instance. The curves originating from the
interactions of sVpr21-40 (A), sVpr25-40 (B), sVpr1-40(C), sVpr1-40 P5,10,14N (D), sVpr30-40 (E), sVpr32-38 (F) and sVpr33-37(G) with CypA were considered
to fit to two state reaction model (sensogram A2-G2) best.
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rate (kd2) constants were calculated, and subsequently
the magnitude of the dissociation constants (KD) could
be calculated (1/((ka1/kd1)*(ka2/kd2)) (Table 1).
The calculated dissociation constants were all of the
same order of magnitude for the N-terminal Vpr peptides
sVpr1-40, sVpr21-40, sVpr25-40, sVpr30-40 and sVpr32-38 con-
taining Pro-35 (Table 1). Reliable dissociation constants
for sVpr1-40 P5,10,14N, which also contains Pro-35 and
binds to CypA (Fig. 6E), could not be determined with
high confidence. This may be due to relatively poor solu-
bility of the latter peptide in aqueous buffer solution at
pH 7.
The two facts, that sVpr1-20 did not bind to CypA in
the Biacore assay (Fig. 6) although CypA was shown by
our NMR studies to interact with these Pro residues of
the peptide as a prolyl cis/trans isomerase (Fig. 3, 5) and
that the presence of Pro-35 on the other hand is
required for binding, indicate the observed specific bind-
ing of N-terminal Vpr peptides to CypA require a bind-
ing region that is structurally dependent on Pro-35.
To identify and determine the specific binding region
of N-terminal Vpr to CypA, SPR studies of the shorter
Vpr peptides sVpr30-40, sVpr32-38 and sVpr33-37 were per-
formed. The sensograms revealed that sVpr30-40and
sVpr32-38 maintain the strong binding to CypA similar
to that of longer N-terminal Vpr peptides (Fig. 8). In
contrast, the shortest peptide sVpr33-37 binds consider-
ably weaker. The remarkably weaker response of the
binding curves of sVpr33-37 to CypA compared with the
longer peptides, demonstrates that the shortest peptide
sequence maintaining strong binding is the heptapeptide
sVpr32-38. Thus the seven-residue motif RHFPRIW
centred at Pro-35 defines the region for strong specific
binding to CypA. In keeping with our findings, Zander
et al. [9] and Ardon et al. [10] reported that CypA co-
immunoprecipitates with wild-type Vpr, while mutation
of Pro-35 caused loss of this phenomenon.
Discussion
As a continuation of our previous discovery of the inter-
action of CypA with Vpr, these interactions have in this
work been characterized in detail at atomic resolution.
Direct experimental evidence that all four conserved Pro
residues in Vpr undergo cis/trans isomerism in aqueous
solution at pH 7 that is catalyzed by CypA was achieved.
Only small amounts of enzyme are required and the
NMR method is sufficiently sensitive to detect these
effects in ratios of substrate to enzyme as high as 672:1.
The apparent differentiation between the results origi-
nating from interaction studies performed by NMR
spectroscopy and SPR indicates a different additional
mode of interaction observed in the latter case. The fact
that only N-terminal Vpr peptides containing Pro-35
bind to CypA in the Biacore assay and strong binding is
maintained in the heptapeptide sVpr32-38, although
CypA also catalyzes prolyl cis/trans interconversions of
Pro-5, 10 and 14 of sVpr1-20 as shown by NMR spectro-
scopy at atomic resolution, is convincing evidence that
CypA only binds specifically to peptides containing the
seven-residue motif RHFPRIW centred at Pro-35 of N-
terminal Vpr. With the exception of Ile-37, residues
comprising the binding region of N-terminal Vpr to
CypA are highly conserved [26]. This region includes
the loop region connecting helices 1 and 2 of Vpr, in
addition to Arg-32 and His-33 that terminates the well-
defined helix 1 of Vpr.
The situation found here is analogous to the NMR
study reported by Bosco et al. [12] where CypA not only
interacts as a chaperone with Pro-90 of N-terminal
HIV-1 Capsid but also selectively catalyzes the prolyl
Table 1 Estimated kinetic constants for binding of HIV-1 N-terminal Vpr peptides to CypA.
Peptide Amino acid sequence Kinetic constants by two state reaction model
KD (M) ka1 (1/Ms)
ka2 (1/s)
kd(1/s)
sVpr21-40 ELLEELKSEAVRHFP35 RIWLH 2.01 × 10-4 ka1 = 466
ka2 = 0.0084
kd1 = 0.164
kd2 = 0.011
sVpr25-40 ELKSEAVRHFP35 RIWLH 4.04 × 10-4 ka1 = 2004
Ka2 = 0.0028
kd1 = 0.9415
kd2 = 0.0173
sVpr1-40 MEQAP5EDQGP10QREP14YNEWTTLELLEELKSEAVRHFP35 RIWLH 2.84 × 10-4 ka1 = 752
ka2 = 0.0073
kd1 = 0.37
kd2 = 0.0099
sVpr1-40 P5,10,14 N MEQAN5EDQGN10QREN14YNEWT TLELLEELKSEAVRHFP35
RIWLH
0.00615* ka1 = 46*
ka2 = 0.0047
kd1 = 0.56*
kd2 = 0.0048
sVpr30-40 AVRHFP35 RIWLH 1.67 × 10-4 ka1 = 2467
ka2 = 0.00145
kd1 = 0.527
kd2 = 0.0053
sVpr32-38 RHFP35 RIW 4.87 × 10-4 ka1 = 924
ka2 = 0.0011
kd1 = 0.67
kd2 = 0.0023
sVpr33-37 HFP35RI 0.00357 ka1 = 120.4
ka2 = 0.00138
kd1 = 0.66
kd2 = 0.0025
*ka1 beyond the values measurable by the Biacore instrument.
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cis/trans interconversion of the Gly-89 -Pro-90 bond.
Crystal structure of the complex of CypA with the N-
terminal HIV-1 Capsid peptide (residues 1-151) revealed
that the binding region of HIV-1 Capsid to CypA
encompasses the nine residues 85 to 93 (PVHAGPIAP)
belonging to a loop region connecting helices 4 and 5,
respectively, of HIV-1 Capsid [39]. Based on X-ray crys-
tallography, Vajdos et al. [40] reported that the HIV-1
Capsid-derived hexapeptide HAGP90IA maintained the
strong interaction with CypA, thus limiting the binding
region of HIV-1 Capsid to include these six residues.
Piotukh et al. [41] used phage display to delineate the
requirements for stable binding of CypA to linear pep-
tide motifs containing the consensus motif FGPXLp that
is present in many human proteins. This binding motif
is quite different from the sequence RHFPRIW found
here that defines the binding region of N-terminal Vpr
to CypA and also differs from the binding region of
HIV-1 Capsid (HAGPIA), indicating that the Pro-depen-
dent binding pocket of CypA is tolerant of substrates
with several different sequences.
Pro-35 in Vpr is located in a loop region separating
helix 1 and helix 2 [25]. Structural data for an N-term-
inal mutant of Vpr in which Pro-35 is exchanged for
Asn indicate a merge of helices 1 and 2 leading to a sig-
nificant conformational change in the hydrophobic core
of Vpr [11]. This will thus disrupt the hydrophobic
interactions of helices 1 and 2 with helix 3 that were
observed by long-range NOEs [25]. The tertiary struc-
ture of wt Vpr consists of three well-defined a-helices
consisting of residues 17-33 (helix 1), 38-50 (helix 2)
and 56-77 (helix 3), respectively, folded around a hydro-
phobic core constituted of Leu, Ile, Val and aromatic
residues [25]. According to Morellet et al. [25], the
hydrophilic accessible domains of Vpr exposed to the
solvent molecules comprise the acidic residues Glu-21,
Glu-22, Glu-24, Glu-25, Asn-28 and Glu-29 of helix 1,
the basic residues Arg-62, Arg-73, Arg-77, Gln-65 and
Gln-66 of helix 3 and the basic residues Arg-80, Arg-87,
Arg-88, Arg-90 and Lys-95 of the flexible C-terminal
domain, respectively. The fact that the mutant Vpr
R80A failed to co-immunoprecipitate with CypA [10]
may indicate that the binding of full-length Vpr to
CypA is also dependent on the maintenance of the ter-
tiary structure of Vpr. Clearly there are at least two
highly conserved residues in the molecule that are cru-
cial for maintaining the interaction of CypA with Vpr,
namely Pro-35 and Arg-80.
Previous literature has indicated that CypA is rela-
tively tolerant as a prolyl cis/trans isomerase to a variety
of different substrates [21]; however, these studies have
been performed exclusively on short peptides comprised
of four amino acids and containing only one Pro resi-
due. To our knowledge catalysis by CypA of prolyl cis/
Figure 8 Characterization of CypA binding region of the N-terminus of Vpr. Synthetic Vpr30-40 (A), Vpr32-38 (B), Vpr33-37(C, D) were tested
for binding to immobilized recombinant CypA using SPR biosensor system. Individual peptides were injected at concentration ranging from 0-
400 μM over CM5 chip immobilized with 980 RU CypA. The curves were best fit to a two state model, and ka1, ka2, kd1, kd2 and KD were
calculated for the respective sensograms (Table 1.).
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trans interconversions of more than one Pro residue in
a peptide containing several Pro residues has not pre-
viously been reported. However, exclusively selective
prolyl cis/trans isomerase catalysis mediated by CypA
on only one Pro unit have been reported for peptides
containing more than one Pro residue [12,13,23].
The binding curves from Biacore analyses of the speci-
fic interaction of Pro-35 were consistent with a two-
state binding interaction model involving a conforma-
tional change during the binding. This is in accord with
the catalysis of prolyl cis/trans isomerism observed by
NMR in solution, indicating that the RHFPRIW motif of
N-terminal Vpr binds the catalytic site of CypA, which
maintains the ability to catalyze the prolyl cis/trans
interconversion during binding.
The fact that CypA specifically binds to the inter-heli-
cal loop region included in the RHFPRIW binding motif
centred at Pro-35, under solution conditions where Vpr
has a relatively random structure, suggests a mechanism
in which CypA may act as a folding chaperone. Whether
this plays a role in the de novo synthesis of Vpr, in which
CypA appears to be involved, remains to be determined
[9]. Clearly the functional consequences of the interac-
tions of CypA still remain to be determined. Further stu-
dies will necessitate the evaluation of these interactions
in the context of the full length Vpr molecule in the var-
ious environments that it encounters in vivo.
Conclusions
Binding of CypA to a defined inter-helical loop region of
HIV-1 Vpr is highly specific, which is analogous to the
previously characterised HIV-1 Capsid-CypA interaction.
The loop region centred at Pro-35 of Vpr comprising
the binding motif to CypA maintains the integrity of the
N-terminal and middle helices of Vpr and is functionally
important for incorporation of Vpr into virus particles
and replication of R5-tropic HIV-1 in human lymphoid
tissue [28]. CypA acts as a catalyst of prolyl cis/trans
interconversions of Pro 5, 10, 14 and 35 of N-terminal
HIV-1 Vpr, which may indicate a folding chaperone role
of CypA in HIV replication compatible with the fact
that inhibitors of CypA, which inhibit CypA-Vpr bind-
ing [9,10] and CypA-mediated prolyl cis/trans catalysis,
also suppress HIV-1 replication in cell culture.
Methods
Peptide synthesis
The synthesis, purification and molecular characteriza-
tion of synthetic Vpr (sVpr) fragments, sVpr1-40, sVpr1-40
P35N, sVpr1-40 P5,10,14N, sVpr1-20, sVpr21-40, sVpr25-40,
sVpr30-40, sVpr32-38 and sVpr33-37 were performed as
described in detail elsewhere [7,19] and all showed the
expected high quality HPLC peaks and correct molecular
masses by MALDI-MS and positive ion ESI-MS.
Cyclosporine A and CypA
Cyclosporine A was purchased from Sigma (C3662; CAS
number 59865-13-3). The procedure on which the puri-
fication of recombinant human CypA is based has pre-
viously been described by others [42]. The E. coli strain
BL21(DE3) (Invitrogen) was transformed with an
pET11c expression vector encoding human CypA [43].
A 4-liter culture of E. coli BL21(DE3) was grown at 37°
C in a LB medium containing ampicillin to an A595 of
0.8 and isopropyl-b-D-thiogalactopyranoside (IPTG) was
added to a final concentration of 1 mM. The incubation
was continued for additional 8 h. The cells were har-
vested (3000 g, 15 min), washed with Tris buffer (1 mM
DTT, 20 mM TrisHCl, pH 7, 8) and 12 g cell pellet was
resuspended in 150 ml of the same buffer. Lysis was
performed on ice using a BL12 sonifier (Branson). After
separation of the cell debris by centrifugation (48000 g,
15 min) nucleic acids were precipitated by protamine
sulphate (0.4% final concentration). The crude cell
extract was dialyzed against the Tris buffer overnight
and loaded onto a DEAE-Sepharose column (HiPrep16/
10, GE Healthcare) equilibrated with 4 column volumes
(CV) of Tris-buffer and the flow-through fractions were
collected, containing essentially pure CypA. These frac-
tions were combined and dialyzed against a 30 mM
MES buffer pH 6.0 overnight. For final purification and
concentration of CypA, the dialyzed solution was loaded
on a MonoS cation exchange column (5/50 GL, GE
Healthcare) which was equilibrated with 4 CV of the
MES buffer. The final elution step of the bound CypA
was performed with a 0-1 M NaCl gradient and yielded
30 mg of highly concentrated and pure CypA fractions,
which were analysed by Coomassie staining and Maldi
MS to check the purity and the correct molecular
weight of the protein (Additional file 1, Fig. S4).
Mass Spectrometry
Matrix assisted laser desorption ionization mass spectra
(MALDI-MS) were recorded on a Voyager-DE PRO
BioSpectrometry Workstation from Applied Biosystems.
Samples were dissolved in 50% aqueous acetonitrile and
a-cyano-4-hydroxycinnamic acid was used as matrix.
Positive ion electrospray ionization mass spectra (ESI-
MS) were recorded on a micromass Q-Tof-2 mass spec-
trometer. Samples were dissolved in 70% aqueous metha-
nol and infused into the electrospray chamber with a
needle voltage of 0.9 kV at a flow rate of 40 nl/min.
Nuclear Magnetic Resonance (NMR) Spectroscopy
2D 1H Total correlation spectroscopy (TOCSY), Nuclear
Overhauser enhancement spectroscopy (NOESY) and
Rotating frame Overhauser enhancement spectroscopy
(ROESY) NMR experiments were performed at 600.13
MHz on a Bruker Avance 600 MHz instrument equipped
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with an UltraShield Plus magnet and a triple resonance
cryoprobe with gradient unit. Individual samples were
dissolved in 600 μl 50 mM aqueous phosphate buffer pH
7.0 containing 10% D2O (v/v), at concentrations between
1-2 mM. The 2D NMR experiments were performed at
300 K without spinning with mixing times of 110 ms for
the TOCSY experiments, 250 ms for the NOESY experi-
ments and 500 ms for the ROESY experiments, respec-
tively. Efficient suppression of the water signal was
achieved with application of excitation sculpting in the 1
D 1H and the 2D 1H TOCSY and NOESY NMR experi-
ments [44] and presat in the 2D 1H ROESY experiments
[45]. 1H signal assignments of the NMR spectra were
achieved by identification of the individual spin systems
in the 2D 1H TOCSY spectra, combined with observa-
tions of sequence-specific short-distance crosspeaks (Ha-
HN i, i+1) in the 2D 1H-1H NOESY spectra [9,46]. Read-
ily recognisable spin systems were used as starting points
for correlation of the individual spin systems observed in
the TOCSY and NOESY spectra with individual residues
in the peptide sequences. Acquisition of data, processing
and spectral analysis were performed with Bruker Top-
spin 1.3 software. Assigned NMR data of the N-terminal
Vpr peptides have been deposited at the BMRB (Acces-
sion number 17003).
Interactions of CypA with sVpr1-20 and sVpr21-40 peptides
After acquisition of 1 D 1H and 2D 1H TOCSY, NOESY
and ROESY NMR spectra of pure sVpr1-20 and sVpr21-40,
50-100 μl 0.11 mM CypA dissolved in aqueous Tris buf-
fer at pH 7 was added to the individual peptide solutions,
followed by acquisition of identical series of NMR spectra
(1 D 1H and 2D 1H TOCSY, NOESY and ROESY) to
those of the pure peptides. Exchange peaks occurring in
the spectra after addition of CypA were identified by sup-
position of analogous NOESY and/or ROESY spectra
prior to and after addition of CypA using Bruker Topspin
1.3 software.
Determination of rate constant for Pro cis/trans
interconversion by ROESY NMR
A series of ROESY experiments of Vpr32-38 (sample con-
centration 4.2 mM) with addition of 50 μl 0.11 mM
CypA (sample concentration of CypA 8.5 μM; total
volume 650 μl); relative proportions of substrate to
enzyme 494:1, maintaining the same experimental con-
dition as described above but with variable mixing time
(500 ms, 450 ms, 400 ms, 350 ms, 300 ms, 250 ms 200
ms 150 ms, 100 ms and 50 ms, respectively) were per-
formed. Volume integration of exchange peaks were car-
ried out with Sparky software [47] and rate constants for
each mixing time were calculated as described in Keller
et al. [48].
Specific inhibition of prolyl cis/trans isomerase
interactions of CypA with sVpr1-20 and sVpr21-40 by
addition of cyclosporine A
The catalytic prolyl cis/trans isomerase interactions of
CypA with sVpr1-20 and sVpr21-40 was inhibited by addi-
tion of excessive amounts of cyclosporine A dissolved in
5 μl deuterated dimethylsulfoxide (DMSO-d6). Addition
of 6 μl pure DMSO did not inhibit the catalytic prolyl
cis/trans isomerase interactions of CypA with a model
peptide showing that CypA keeps its enzyme activity in
1% DMSO solution. The disappearance of NMR
exchange peaks, originating from the catalytic prolyl cis/
trans isomerase interactions of CypA with sVpr1-20 and
sVpr21-40, after addition of cyclosporine A was revealed
by supposition of analogous NOESY and ROESY spectra
prior to and after addition of cyclosporine A, using Bru-
ker Topspin 1.3 software.
Biacore Spectroscopy
SPR measurements were performed at 25°C on a Bia-
core T100 instrument (Biacore AB, Uppsala, Sweden)
equipped with a CM5 research-grade sensor chip.
CypA was immobilized in FC 2 and FC 4 to 180 and
918 RU (response units) respectively, using standard
amine-coupling chemistry in two flow cells. FC 1 and
FC 3 were treated according to FC 2 and FC 4 except
for CypA immobilisation and functioned as reference
cells. The synthetic Vpr peptides sVpr1-20, sVpr21-40,
sVpr25-40, sVpr30-40, sVpr32-38 and sVpr33-37 were dis-
solved at four concentrations ranging from 50 to 400
μM in the running buffer (HBS-P buffer pH 7.4). Due
to restricted solubility sVpr1-40, sVpr1-40 P35N and
sVpr1-40 P5,10,14N were dissolved at lower concentra-
tions ranging from 25-200 μM in the same buffer. The
samples were injected over the flow cells at a flow
rate of 30 μl/min. Data were collected at 2.5 Hz dur-
ing the 60 s association and 120 s dissociation phase,
and were automatically corrected for bulk buffer
effects and unspecific binding of Vpr peptides to the
chip matrix.
Analysis of biosensor data
Affinity, association and dissociation rate constants were
obtained from sensograms by the Biacore T100 evalua-
tion software version 2.0.1 in accordance with the global
curve fit model. Sensorgram data for the four different
concentrations were fitted to several binding models
including 1:1 (Langmuir) binding model (A+B ↔ AB),
two-state reaction (conformational change) model (A+B
↔ AB ↔ AB*) and heterogeneous ligand model (inter-
action one: A+B1 ↔ AB1; interaction two: A+B2 ↔
AB2). Kinetic constants were calculated for the best
fitted model.
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Additional material
Additional file 1: Tables of 1H Chemical shifts of N-terminal Vpr
peptides. MALDI-TOF Mass spectrum of CypA. Chemical shift differences
of the Haα-protons between the experimental values and those for
random coil residues, for sVpr1-20 and sVpr21-40. Calculated reaction rate
constants for the prolyl cis/trans interconversion of Pro-35 of sVpr32-38.
Optimised fit residuals of SPR sensograms. Peak intensities of cis/trans
crosspeaks versus diagonal signal intensities influenced by mixing times
observed in the ROESY spectra of sVpr32-38.
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